title: SIRT1 expression is associated with good prognosis for head and neck squamous cell carcinoma patients.
abstract: OBJECTIVE
  SIRT1, class III histone deacetylase, has been described to be up-regulated in various malignancies. However, the opposite results have been reported in other malignancies. Therefore, we investigated SIRT1 expression to clarify its biological behavior and identify its usefulness as a biomarker for head and neck squamous cell carcinoma (HNSCC).
  
  
  METHODS
  SIRT1 expression was assessed by immunohistochemistry (IHC) conducted using samples from 437 consecutive HNSCC patients. Acetylated histone status and p53 expression were also examined.
  
  
  CONCLUSIONS
  IHC revealed 79.6% staining of SIRT1 in HNSCC, while almost all normal tissues showed positive staining. SIRT1 expression predominated in cases involving patients aged >65 years, lymph node negative, and early clinical stage cases. It was positively and statistically correlated with expression of acetylated histone H3K9 and H4K16, but not with p53. Multivariate analyses revealed that expression of SIRT1 was an independent and good indicator of prognosis.
authors: Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan.
authors: Akira
authors: A
authors: Noguchi
authors: Xiaohan
authors: X
authors: Li
authors: Akira
authors: A
authors: Kubota
authors: Keiji
authors: K
authors: Kikuchi
authors: Yoichi
authors: Y
authors: Kameda
authors: Hauchaun
authors: H
authors: Zheng
authors: Yohei
authors: Y
authors: Miyagi
authors: Ichiro
authors: I
authors: Aoki
authors: Yasuo
authors: Y
authors: Takano
mesh_terms: D000367:Age Factors; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis; D002294:Carcinoma, Squamous Cell / Q000235:genetics / Q000473:pathology*; D015331:Cohort Studies; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics; D006258:Head and Neck Neoplasms / Q000235:genetics / Q000473:pathology*; D006655:Histone Deacetylases / Q000032:analysis; D006657:Histones / Q000032:analysis; D006801:Humans; D007150:Immunohistochemistry; D007822:Laryngeal Neoplasms / Q000473:pathology; D008198:Lymph Nodes / Q000473:pathology; D008297:Male; D020360:Neoadjuvant Therapy; D060787:Neoplasm Grading; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D010610:Pharyngeal Neoplasms / Q000473:pathology; D011379:Prognosis; D056564:Sirtuin 1 / Q000032:analysis* / Q000235:genetics; D015996:Survival Rate; D014062:Tongue Neoplasms / Q000473:pathology; D016159:Tumor Suppressor Protein p53 / Q000032:analysis
chemical_list: D014408:Biomarkers, Tumor; D006657:Histones; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; C447939:SIRT1 protein, human; D056564:Sirtuin 1; D006655:Histone Deacetylases